Sangamo Therapeutics, Inc. 0R1D.L Stock
Sangamo Therapeutics, Inc. Price Chart
Sangamo Therapeutics, Inc. 0R1D.L Financial and Trading Overview
Sangamo Therapeutics, Inc. stock price | 0.56 USD |
Previous Close | 1.25 USD |
Open | 0 USD |
Bid | 0 USD x N/A |
Ask | 0 USD x N/A |
Day's Range | 0 - 0 USD |
52 Week Range | 0 - 6.27 USD |
Volume | 1.71K USD |
Avg. Volume | 4.26K USD |
Market Cap | 1.47M USD |
Beta (5Y Monthly) | 1.068309 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.213 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0R1D.L Valuation Measures
Enterprise Value | 46.84M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.006086929 |
Price/Book (mrq) | 0.6031218 |
Enterprise Value/Revenue | 0.194 |
Enterprise Value/EBITDA | -0.703 |
Trading Information
Sangamo Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 1.068309 |
52-Week Change | -67.53% |
S&P500 52-Week Change | 20.43% |
52 Week High | 6.27 USD |
52 Week Low | 0 USD |
50-Day Moving Average | 1.4 USD |
200-Day Moving Average | 3.41 USD |
0R1D.L Share Statistics
Avg. Volume (3 month) | 4.26K USD |
Avg. Daily Volume (10-Days) | 4.28K USD |
Shares Outstanding | 102.09M |
Float | 147.27M |
Short Ratio | N/A |
% Held by Insiders | 14.40% |
% Held by Institutions | 62.63% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -52.76% |
Operating Margin (ttm) | -32.94% |
Gross Margin | -5.60% |
EBITDA Margin | -27.65% |
Management Effectiveness
Return on Assets (ttm) | -9.067% |
Return on Equity (ttm) | -37.95% |
Income Statement
Revenue (ttm) | 241.02M USD |
Revenue Per Share (ttm) | 1.51 USD |
Quarterly Revenue Growth (yoy) | 459.50% |
Gross Profit (ttm) | -138599000 USD |
EBITDA | -66650000 USD |
Net Income Avi to Common (ttm) | -127168000 USD |
Diluted EPS (ttm) | -1.213 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 205.39M USD |
Total Cash Per Share (mrq) | 1.2 USD |
Total Debt (mrq) | 37.7M USD |
Total Debt/Equity (mrq) | 11.23 USD |
Current Ratio (mrq) | 3.926 |
Book Value Per Share (mrq) | 1.954 |
Cash Flow Statement
Operating Cash Flow (ttm) | -230952000 USD |
Levered Free Cash Flow (ttm) | -83843376 USD |
Profile of Sangamo Therapeutics, Inc.
Country | United Kingdom |
State | CA |
City | Brisbane |
Address | 7000 Marina Blvd |
ZIP | 94005 |
Phone | 510 970 6000 |
Website | https://www.sangamo.com |
Industry | |
Sector(s) | |
Full Time Employees | 478 |
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
Q&A For Sangamo Therapeutics, Inc. Stock
What is a current 0R1D.L stock price?
Sangamo Therapeutics, Inc. 0R1D.L stock price today per share is 0.56 USD.
How to purchase Sangamo Therapeutics, Inc. stock?
You can buy 0R1D.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Sangamo Therapeutics, Inc.?
The stock symbol or ticker of Sangamo Therapeutics, Inc. is 0R1D.L.
How many shares does Sangamo Therapeutics, Inc. have in circulation?
The max supply of Sangamo Therapeutics, Inc. shares is 1.24M.
What is Sangamo Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Sangamo Therapeutics, Inc. PE Ratio is now.
What was Sangamo Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Sangamo Therapeutics, Inc. EPS is -1.213 USD over the trailing 12 months.